Latest News and Press Releases

Groundbreaking Study Demonstrates Safety and Tolerability of Oral Mucosal Immunotherapy (OMIT) for Peanut Allergy Using Toothpaste

Intrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry Events

Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board.

OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects

New study is the first to evaluate Oral Mucosal Immunotherapy (OMIT) for the treatment of food allergy

Inimmune Corporation and Intrommune Therapeutics announce a collaboration to advance a revolutionary rapid, long-acting oral mucosal allergy immunotherapy

Intrommune Therapeutics Presents Positive Results of Phase 1 OMEGA Study Investigating the Safety of INT301 Toothpaste for the Treatment Peanut Allergy

NEW YORK, July 25, 2023 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...

Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose...

Appointment of Stuart Loesch as President Leverages His Strong Leadership Abilities and Extensive Expertise in Allergy and Pharmaceutical Development Appointment of William Berger, MD, MBA as Head of...